MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 78.90% | 75.82% | 66.92% | 59.40% | 63.80% |
| Total Depreciation and Amortization | -92.37% | -92.48% | -79.68% | -66.52% | -53.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -379.10% | -413.81% | -389.45% | -186.49% | -91.22% |
| Change in Net Operating Assets | -41.90% | -54.94% | -51.48% | 40.70% | 5,881.02% |
| Cash from Operations | -916.67% | -399.82% | -219.31% | 89.81% | 100.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -195.14% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 102.41% | 85.17% | 70.40% | -117.16% |
| Cash from Investing | 477.70% | 397.64% | 361.50% | 336.30% | -126.35% |
| Total Debt Issued | -- | -- | -- | -- | -100.44% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -228.22% | 107.95% | 107.95% | 75.00% | -98.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.89% | 105.62% | 78.20% | 100.00% | 101.10% |